Antares (thiazotic acid morpholinium salt) solution for injections 50 mg/ml. 4 ml. ampoules №10

active ingredient: morpholinium salt of thiazoic acid;

1 ml of solution contains morpholinium salt of thiazoic acid, in terms of 100% substance – 50 mg, which is equivalent to 33.3 mg of thiazoic acid;

excipient: water for injection.

Injection.

basic physico-chemical properties: transparent colorless or slightly yellowish liquid.

cardiac drugs. Other cardiac drugs. ATX code C01E B23.

The pharmacological effect of thiazoic acid is due to anti-ischemic, membrane-stabilizing, antioxidant and immunomodulatory effects.

The effect of the drug is realized by enhancing the compensatory activation of anaerobic glycolysis and the activation of oxidation processes in the Krebs cycle while maintaining the intracellular fund of adenosine triphosphate. The presence in the structure of the thiazoic acid molecule of sulfur thiol, which is characterized by redox properties, and tertiary nitrogen, which binds an excess of hydrogen ions, causes the activation of the antioxidant system. The strong reducing properties of the thiol group cause a reaction with reactive oxygen species and lipid radicals. Reactivation of antiradical enzymes – superoxide dismutase, catalase and glutathione peroxidase – prevents the initiation of reactive oxygen species.

Thiazotic acid inhibits the processes of lipid oxidation in ischemic areas of the myocardium, reduces the sensitivity of the myocardium to catecholamines, prevents progressive inhibition of the contractile function of the heart, stabilizes and reduces, respectively, the zone of necrosis and myocardial ischemia. Improving the rheological properties of blood is carried out by activating the fibrinolytic system. Improving the processes of myocardial metabolism, increasing its contractility, contributing to the normalization of the heart rhythm allows us to recommend thiazoic acid for the treatment of patients with various forms of coronary heart disease.

The maximum concentration of thiazoic acid in the blood plasma is achieved with intramuscular injection after 0.84 hours, with intravenous administration – after 0.1 hour. Binding to blood proteins does not exceed 10%. Thiazotic acid accumulates mainly in the kidneys – 31%. In a significant amount, it accumulates in the large intestine, heart, spleen, least of all – in the small intestine and lungs (1-2%).

In the complex treatment of coronary heart disease: angina pectoris, myocardial infarction.

• Hypersensitivity to thiazoic acid; acute renal failure.
• During pregnancy and breastfeeding.
• Children’s age (up to 18 years).